New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
05:32 EDTREGN, BAYRYRegeneron Eylea injection receives EU approval for DME treatment
Regeneron Pharmaceuticals (REGN) announced that Eylea Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema, or DME. Bayer Healthcare (BAYRY) plans to launch Eylea in DME in the EU this quarter. Bayer HealthCare and Regeneron are collaborating on the global development of Eylea.
News For REGN;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
06:58 EDTBAYRYBayer head says content with size of animal health division, Reuters says
Bayer CEO Marijn Dekkers said that it feels content with the size of the company's animal health division and believes that the business can "very well operate on its own," according to Reuters, citing comments from Dekkers. Dekkers noted that any profits from a separate listing of the company's MaterialScience business could be utilized to reduce debt and not go toward the animal health unit. Reference Link
October 29, 2014
13:03 EDTBAYRYDuPont sells Land Management business assets to Bayer CropScience
Subscribe for More Information
10:00 EDTBAYRYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AMC Networks (AMCX) upgraded to Buy from Hold at ISI Group... Abbott (ABT) upgraded to Buy from Hold at Deutsche Bank... Ahold (AHONY) upgraded to Overweight from Neutral at JPMorgan... Alere (ALR) upgraded to Buy from Hold at Craig-Hallum... Ambev (ABEV) upgraded to Buy from Neutral at Goldman... Bayer (BAYRY) upgraded to Outperform from Market Perform at Bernstein... C.H. Robinson (CHRW) upgraded to Buy from Neutral at BofA/Merrill... Cliffs Natural (CLF) upgraded to Outperform from Neutral at Macquarie... HCC Insurance (HCC) upgraded at Raymond James... Hannon Armstrong (HASI) upgraded to Buy from Neutral at BofA/Merrill... Jamba (JMBA) upgraded to Outperform from Neutral at Wedbush... Midway Gold (MDW) upgraded to Speculative Buy from Hold at Canaccord... PG&E (PCG) upgraded to Buy from Hold at Deutsche Bank... RWE AG (RWEOY) upgraded to Neutral from Underweight at JPMorgan... Starwood (HOT) upgraded to Buy from Hold at Craig-Hallum... Total System (TSS) upgraded to Overweight from Equal Weight at Stephens.
06:53 EDTBAYRYBayer upgraded to Outperform from Market Perform at Bernstein
Subscribe for More Information
October 27, 2014
07:22 EDTBAYRYAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 24, 2014
08:04 EDTREGNRegeneron price target raised to $460 from $350 at Canaccord
Subscribe for More Information
October 22, 2014
13:37 EDTBAYRYPE firms may bid on Bayer's MaterialScience unit, Reuters says
Subscribe for More Information
October 20, 2014
07:16 EDTREGNAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
07:11 EDTBAYRYAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
07:10 EDTREGNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:02 EDTREGNRegeneron Sanofi begins dosing in Phase 3 study of dupilumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis, or AD, that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical program for dupilumab, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of demonstrating the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks.
October 17, 2014
09:06 EDTREGNAmgen files patent infringement lawsuit against Sanofi, Regeneron
Amgen (AMGN) announced that it filed a lawsuit in the United States District Court of Delaware against Sanofi (SNY), Aventisub, formerly doing business as Aventis Pharmaceuticals, and Regeneron Pharmaceuticals (REGN) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, or PCSK9. By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S. Amgen previously announced submission of a Biologics License Application to the FDA for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28.
07:07 EDTREGNRegeneron announces EYLEA results from NIH study
Subscribe for More Information
October 16, 2014
08:36 EDTREGNRegeneron Genetics Center announces new collaborations and appointments
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use